Physiological similarities between dogs and humans, and conserved genetics between some dog and human cancers, can allow pet dogs to serve as useful models for studying new cancer drugs, says Dr Timothy Fan of the University of Illinois.
Timothy Fan, professor of veterinary clinical medicine. With his personal dog, Ember photo by L. Brian Stauffer
In a meeting sponsored by the National Cancer Policy Forum of the National Academies’ Institute of Medicine in Washington, D.C., Fan and 15 other experts in the field described the benefits of using pet dogs with naturally occurring (rather than laboratory-induced) tumors in early cancer drug trials.
“We have a lot of dogs in the United States, approximately 70 million of them, and it’s believed that about 25 percent of pet dogs will develop some form of cancer in their lifetime,” he said. “We’re using dogs to help guide drug development for people, but at the same time we’re offering new, innovative therapies that would otherwise never be available to dogs, to help them as well.”
Several attributes make pet dogs attractive subjects for such studies, Fan said.
“Dogs tend to develop cancer as a geriatric population, just like people,” he said. “Because the tumors develop spontaneously, there is heterogeneity in that tumor population, as a human being would have. The size of the tumors and the speed of growth of those tumors are comparable in dogs and human beings. So there are many attributes of a dog that develops cancer spontaneously that recapitulate the biology that we see in people.”
Some studies have already begun using dogs to test new cancer therapies. Starting in 2007, for example, Fan began testing an anti-cancer drug called PAC-1 in pet dogs with naturally occurring lymphomas and osteosarcomas. The results in dogs allowed the scientists to advance PAC-1 as a potential therapy against human cancers. The drug is now in phase I human clinic trials.
“Another example in which dogs have been important in demonstrating drug activity was an anti-cancer compound produced by the pharmaceutical company Gilead Sciences,” he said. “The company produced a pro-drug, which must be activated by a naturally occurring enzyme in human leukocytes before it can become effective. Mice and rats lack this enzyme, but dogs have it, so the compound was tested in dogs.”
There also are limitations to the use of pet dogs in cancer drug trials.
“There are some tumors that will not be that relevant,” Fan said. “Colon cancer, for example, is heavily driven by diet, and we don’t see much colon cancer in dogs. So pet dogs might not be a suitable model for colon cancer in humans.”
“There is heterogeneity in the human population and in dogs. So I would argue that if your drug agent produces positive results in dogs, that would give me greater confidence that those findings would be translatable to people.”
Source: University of Illinois media release